Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications

Therapeutic Apheresis and Dialysis

Volumn 13, Issue 6, 2009, Pages 534-539

  Yamagishi, Sho Ichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Advanced glycation end product; Advanced glycation end product receptor; Diabetic vascular complications; Oxidative stress

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; AST 120; PIGMENT EPITHELIUM DERIVED FACTOR; PYRIDOXAL 5 PHOSPHATE; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ANTIOXIDANT ACTIVITY; CHRONIC KIDNEY FAILURE; CROSS LINKING; DEHYDRATION; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DIET; FOOD COMPOSITION; GENE EXPRESSION REGULATION; GLOMERULOSCLEROSIS; GLYCATION; HUMAN; KIDNEY FAILURE; NONHUMAN; OXIDATIVE STRESS; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN FUNCTION; REACTION ANALYSIS; REVIEW; THROMBOSIS; VASCULITIS;

ANIMALS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; OXIDATIVE STRESS; RECEPTORS, IMMUNOLOGIC;

EID: 71949107479     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2009.00775.x     Document Type: Review

References (26)

1. Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005 11 : 2279 2299.
2. Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005 353 : 2643 2653.
3. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008 359 : 1577 1589.
4. Yamagishi S, Nakamura K, Matsui T, Noda Y, Imaizumi T. Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication. Curr Pharm Des 2008 14 : 487 495.
5. Sato T, Iwaki M, Shimogaito N, Wu X, Yamagishi S, Takeuchi M. TAGE (toxic AGEs) theory in diabetic complications. Curr Mol Med 2006 6 : 351 358.
6. Yamagishi S, Amano S, Inagaki Y et al. Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes. Biochem Biophys Res Commun 2002 290 : 973 978.
7. Yamagishi S, Inagaki Y, Amano S, Okamoto T, Takeuchi M, Makita Z. Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties. Biochem Biophys Res Commun 2002 296 : 877 882.
8. Yamagishi S, Matsui T, Nakamura K, Ueda S, Noda Y, Imaizumi T. Pigment epithelium-derived factor (PEDF): its potential therapeutic implication in diabetic vascular complications. Curr Drug Targets 2008 9 : 1025 1029.
9. Yamagishi S, Nakamura K, Matsui T et al. Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J Biol Chem 2006 281 : 20213 20220.
10. Tombran-Tink J, Barnstable CJ. PEDF: a multifaceted neurotrophic factor. Nat Rev Neurosci 2003 4 : 628 636.
11. Yamagishi SI, Nakamura K, Matsui T, Yoshida T, Takeuchi M, Imaizumi T. Pigment epithelium-derived factor (PEDF) blocks advanced glycation end product (AGE)-induced angiogenesis in vitro. Horm Metab Res 2007 39 : 233 235.
12. Yamagishi S, Matsui T, Nakamura K, Takeuchi M, Imaizumi T. Pigment epithelium-derived factor (PEDF) prevents diabetes- or advanced glycation end products (AGE)-elicited retinal leukostasis. Microvasc Res 2006 72 : 86 90.
13. Yamagishi S, Matsui T, Nakamura K, Yoshida Y, Takeuchi M, Inoue H. Pigment-epithelium-derived factor suppresses expression of receptor for advanced glycation end products in the eye of diabetic rats. Ophthalmic Res 2007 39 : 92 7.
14. Yokoi M, Yamagishi S, Takeuchi M et al. Elevations of AGE and vascular endothelial growth factor with decreased total antioxidant status in the vitreous fluid of diabetic patients with retinopathy. Br J Ophthalmol 2005 89 : 673 675.
15. Yokoi M, Yamagishi S, Sato A et al. Positive association of pigment epithelium-derived factor (PEDF) with total anti-oxidant capacity in the vitreous fluid of patients with proliferative diabetic retinopathy. Br J Ophthalmol 2007 91 : 885 887. (Pubitemid 47013096)
16. Yamagishi S, Fukami K, Ueda S, Okuda S. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr Drug Targets 2007 8 : 952 959.
17. Yamagishi S, Inagaki Y, Okamoto T et al. Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem 2002 277 : 20309 20315. (Pubitemid 34967325)
18. Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koka K, Takeuchi M. Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells. Kidney Int 2003 63 : 464 473.
19. Ziyadeh FN, Hoffman BB, Han DC et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000 97 : 8015 8020.
20. Yamamoto Y, Kato I, Doi T et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001 108 : 261 268.
21. Wendt TM, Tanji N, Guo J et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003 162 : 1123 1137.
22. Wang JJ, Zhang SX, Lu K et al. Decreased expression of pigment epithelium-derived factor is involved in the pathogenesis of diabetic nephropathy. Diabetes 2005 54 : 243 250.
23. Wang JJ, Zhang SX, Mott R et al. Salutary effect of pigment epithelium-derived factor in diabetic nephropathy: evidence for antifibrogenic activities. Diabetes 2006 55 : 1678 1685.
24. Yamagishi S, Ueda S, Okuda S. Food-derived advanced glycation end products (AGEs): a novel therapeutic target for various disorders. Curr Pharm Des 2007 13 : 2832 2836.
25. Uribarri J, Peppa M, Cai W et al. Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients. Am J Kidney Dis 2003 42 : 532 538. (Pubitemid 37048129)
26. Ueda S, Yamagishi S, Takeuchi M et al. Oral adsorbent AST-120 decreases serum levels of AGEs in patients with chronic renal failure. Mol Med 2006 12 : 180 184.